| News for nuclear medicine and molecular imaging professionals |  |
| |
|
The news summaries appearing in SNM SmartBrief are based on original information from multiple
internet sources and are produced by SmartBrief, Inc., an independent e-mail newsletter publisher.
The items below are not selected or reviewed by SNM prior to publication. Questions and comments may
be directed to SmartBrief at snm@smartbrief.com.
|
| Top Story |  |  |
|
- Study pinpoints flaws in NCI's clinical trial system
Cancer centers participating in the National Cancer Institute's Clinical Trials Cooperative Group program lose money after the beginning stages because all of it is spent early in the process, leaving none for follow-up, a study published in the Journal of Clinical Oncology found. Cancer centers must then start new clinical trials to fund follow-up in the older, ongoing trials. Instead, the NCI should use the model for industry-funded trials, disbursing funds as patients hit certain milestones during treatment and as they come back for follow-up visits, the researchers suggest. Reuters
(4/11)     
| Clinical News & Research | | |
|
- Ampio to test ORP technology in clinical trials
Ampio Pharmaceuticals said it has finished enrolling patients in its oxidation reduction potential trials. The trial will involve emergency department patients who have chest pain and are being evaluated with PET/CT scans, patients with stroke symptoms and those who have experienced trauma, such as traumatic brain injury. PR Newswire/News release
(4/12)
| Industry Report | | |
|
| News from the Field | | |
|
- Drugmakers should have to release complete trial data
 Drugmakers in the U.S. are not required to release full clinical trial reports to researchers or the public, and the FDA does not disclose the data that regulators review in the drug approval process. The result can be use of a drug based on incomplete data published in journal articles, potentially at great public expense, as in the case of Roche Holding's Tamiflu, write research fellow Peter Doshi and epidemiologist Tom Jefferson. The European Medicines Agency intends to release clinical study data after regulators review a manufacturer’s application, and the FDA should follow suit, the scientists argue. The New York Times (tiered subscription model)
(4/10)
| International Developments | | |
|
| Health Policy | | |
|
- Raise public health spending to $24B, IOM report says
An Institute of Medicine report says the U.S. should more than double federal spending on public health to $24 billion a year and create a minimum set of services each community should get from public health departments. The report suggests a tax on medical care to help cover the extra spending but adds that health costs would decline over time due to lower obesity rates and less use of tobacco. The Hill/Healthwatch blog
(4/10)
| Advancing Health Care | | |
|
- U.S. tech chief talks about innovation and government
 Many of the same principles for innovation apply in both the public and private sectors, says U.S. Chief Technology Officer Todd Park. The FDA's Entrepreneurs in Residence and Innovation Pathway programs are like private-sector lean startups, he says. The former is pairing the government's "best internal innovators ... with entrepreneurs with highly complementary experiences and expertise," and the latter is "engaging customers and stakeholders as soon as possible, co-inventing an optimal solution through hyper-rapid iteration." FDA Voice blog
(4/10)
| From SNM | | |
|
- The proven performance booster: "Steves' Review of Nuclear Medicine Technology"
Get instant access to 200 self-evaluation questions, plus essential content on CT and PET in the new Steves' Review of Nuclear Medicine Technology, 4th edition. This detailed overview of nuclear medicine technology — updated and expanded to cover patient care, instrumentation, nuclear oncology, electrocardiography, interventional drugs and new therapeutic agents — is complemented by hundreds of self-evaluation questions and answers mirroring the structure of national certification examinations. Learn more.
| SmartQuote | | |
|
 | Believe and act as if it were impossible to fail."
--Charles F. Kettering,
American inventor
|
| |
| |
|
Read more at SmartBrief.com |
|
A powerful website for SmartBrief readers including:
|
|
|
|
| |
| |
| | Recent SNM SmartBrief Issues:
- Thursday, April 12, 2012
- Wednesday, April 11, 2012
- Tuesday, April 10, 2012
- Monday, April 09, 2012
- Friday, April 06, 2012
| | | Lead Editor: Melissa Turner
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004 | |
| |
|
| © 1999-2012 SmartBrief, Inc.® Legal Information |
|
